We are live on ! Find out more
PM

Prosight Management Portfolio holdings

AUM $610M
1-Year Est. Return 40.86%
This Fund
S&P 500
This Quarter Est. Return
-3.33%
1 Year Est. Return
+40.86%
3 Year Est. Return
+46.17%
5 Year Est. Return
+1.2%
10 Year Est. Return
–
AUM
$182M
AUM Growth
+$21.8M
Cap. Flow
+$28.1M
Cap. Flow %
15.45%
Top 10 Hldgs %
56.02%
Holding
60
New
14
Increased
20
Reduced
9
Closed
17

Top Buys

Rank Stock Value
1
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$10.6M
2
ALBO
Albireo Pharma Inc
ALBO
+$4.64M
3
ACCD
Accolade Inc
ACCD
+$4.6M
4
AMED
Amedisys
AMED
+$4.16M
5
HUM icon
Humana
HUM
+$3.82M

Top Sells

Rank Stock Value
1
PRTA icon
Prothena Corp
PRTA
+$6.13M
2
HAE icon
Haemonetics
HAE
+$6.04M
3
EHC icon
Encompass Health
EHC
+$4.46M
4
RCM
R1 RCM Inc. Common Stock
RCM
+$3.82M
5
ZBH icon
Zimmer Biomet
ZBH
+$2.8M

Sector Composition

Rank Sector Weight
1 Healthcare 90.68%
2 Industrials 2.27%
3 Financials 1.02%
4 Energy 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ABBV icon
26
AbbVie
ABBV
$458B
$2.67M 1.47%
+24,800
New +$2.83M
IOVA icon
27
CALL
Iovance Biotherapeutics
IOVA
$2.23B
$2.47M 1.36%
+100,000
New +$2.36M
EHC icon
28
Encompass Health
EHC
$11.2B
$2.38M 1.31%
39,780
-70,836
-64% -$4.46M
PRQR icon
29
ProQR Therapeutics
PRQR
$243M
$2.36M 1.3%
282,256
-137,744
-33% -$900K
IRTC icon
30
iRhythm Holdings
IRTC
$3.59B
$2.19M 1.2%
37,396
+17,196
+85% +$911K
ZBH icon
31
Zimmer Biomet
ZBH
$17.7B
$1.9M 1.05%
13,390
-19,055
-59% -$2.8M
PANA
32
DELISTED
Panacea Acquisition Corp. II Class A Ordinary Shares
PANA
$1.85M 1.02%
+188,940
New +$1.87M
WAT icon
33
Waters Corp
WAT
$36.8B
$1.43M 0.79%
+4,000
New +$1.57M
UNH icon
34
UnitedHealth
UNH
$382B
$1.29M 0.71%
3,300
-1,700
-34% -$704K
CLLS
35
Cellectis
CLLS
$286M
$1.1M 0.6%
87,103
+1,067
+1% +$14.8K
SIOX
36
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$1.07M 0.59%
493,208
+237,093
+93% +$516K
ASMB icon
37
Assembly Biosciences
ASMB
$506M
$924K 0.51%
22,136
+9,712
+78% +$407K
ALEC icon
38
Alector
ALEC
$164M
$625K 0.34%
+27,378
New +$767K
LFST icon
39
Lifestance Health
LFST
$4.16B
$562K 0.31%
+38,774
New +$747K
ORGO icon
40
Organogenesis Holdings
ORGO
$308M
$541K 0.3%
38,000
+12,900
+51% +$200K
ONCR
41
DELISTED
Oncorus, Inc.
ONCR
$518K 0.29%
55,411
+5,411
+11% +$61.8K
MDXG icon
42
MiMedx Group
MDXG
$626M
$268K 0.15%
+44,225
New +$498K
APTO
43
DELISTED
Aptose Biosciences, Inc.
APTO
$154K 0.08%
157
-139
-47% -$174K
ADMA icon
44
ADMA Biologics
ADMA
$1.92B
– –
-115,100
Closed -$184K
AUPH icon
45
CALL
Aurinia Pharmaceuticals
AUPH
$1.97B
– –
-67,200
Closed -$871K
AUPH icon
46
Aurinia Pharmaceuticals
AUPH
$1.97B
– –
-130,000
Closed -$1.69M
CLOV icon
47
Clover Health Investments
CLOV
$2.28B
– –
-79,100
Closed -$1.05M
EVH icon
48
Evolent Health
EVH
$475M
– –
-52,023
Closed -$1.1M
MDT icon
49
Medtronic
MDT
$107B
– –
-11,000
Closed -$1.36M
NUVB icon
50
Nuvation Bio
NUVB
$2.24B
– –
-91,694
Closed -$854K
1
2
3

Similar funds

PL
Pandi LLC Leawood, Kansas $610M AUM 14.97% 1-Year Est. Return
BFC
Blue Fin Capital Warren, Rhode Island $610M AUM 26.46% 1-Year Est. Return
DCM
DGS Capital Management Jersey City, New Jersey $609M AUM 44.78% 1-Year Est. Return
SAM
Strategy Asset Managers Pasadena, California $609M AUM 32.56% 1-Year Est. Return
CBB
Citizens Business Bank Ontario, California $610M AUM 27.86% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
FFWA
FRG Family Wealth Advisors Bellevue, Washington $611M AUM 25.92% 1-Year Est. Return
CIP
Convergence Investment Partners Palm Beach Gardens, Florida $611M AUM 61.48% 1-Year Est. Return

Prosight Management's Q3 2021 Portfolio in Review

As of Q3 2021, Prosight Management held 60 positions worth $182M, up 14% from $160M the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Prosight Management deployed $28.1M of net new capital in Q3 2021, opening 14 new positions and adding to 20 existing holdings. Its largest new stake was Accolade Inc: 97,988 shares worth $4.13M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 95% a quarter earlier, followed by Industrials and Financials.

On the sell side, the largest reduction was Prothena Corp, an estimated $6.13M trimmed.

  • Prosight Management's largest Q3 2021 buy was Accolade Inc: 97,988 shares worth $4.13M.
  • Prosight Management added most to Lakefront Biotherapeutics American Depositary Shares in Q3 2021, an estimated $10.6M increase.
  • Prosight Management's biggest Q3 2021 reduction was Prothena Corp, cutting an estimated $6.13M.
  • Prosight Management fully exited R1 RCM Inc. Common Stock in Q3 2021, selling an estimated $3.82M.
  • Prosight Management's ten largest holdings make up 56% of its $182M portfolio in Q3 2021.
  • Prosight Management opened 14 new positions and closed 17 in Q3 2021.
  • Prosight Management's portfolio value rose 14% quarter-over-quarter to $182M.

Based on Prosight Management's 13F filing for Q3 2021, filed 12 Nov 2021.